Journal: The Journal of International Medical Research

Article Title: Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin

doi: 10.1177/03000605211022297

Figure Lengend Snippet: Representative histopathological features of pseudomyxoma peritonei: histological morphology of low-grade mucinous carcinoma (LGMC) (a), high-grade mucinous carcinoma (HGMC) (b) and high-grade with signet ring cells (HGMC-S) (c) (all haematoxylin and eosin; scale bar 50 µm); strong positive staining for carcinoembryonic antigen in LGMC (d), HGMC (e) and HGMC-S (f); weak focal nuclear staining of p53 in LGMC (g); complete lack of stained tumour nuclei for p53 in HGMC (h); strong positive staining for p53 in HGMC-S (i); low Ki67 LI in LGMC (j); high Ki67 LI in HGMC (k) and HGMC-S (l) (d–l, EnVision staining; scale bar 50 µm). The colour version of this figure is available at: http://imr.sagepub.com .

Article Snippet: Immunohistochemical staining was performed using primary mouse monoclonal antibodies against Ki67 (clone UMAB107 ready to use; OriGene China, Beijing, China), p53 (clone DO7 ready to use; OriGene China) and CEA (clone COL1 ready to use; OriGene China) that were processed in automated staining equipment (INTELLIPATH FLX®; Biocare Medical, Pacheco, CA, USA).

Techniques: Staining

Journal: The Journal of International Medical Research

Article Title: Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin

doi: 10.1177/03000605211022297

Figure Lengend Snippet: Kaplan–Meier survival curves of patients with pseudomyxoma peritonei stratified according to the following: (a) histological grade; (b) Ki67 immunostaining; (c) p53 status; (d) Ki67 and p53 subgroups. The colour version of this figure is available at: http://imr.sagepub.com .

Article Snippet: Immunohistochemical staining was performed using primary mouse monoclonal antibodies against Ki67 (clone UMAB107 ready to use; OriGene China, Beijing, China), p53 (clone DO7 ready to use; OriGene China) and CEA (clone COL1 ready to use; OriGene China) that were processed in automated staining equipment (INTELLIPATH FLX®; Biocare Medical, Pacheco, CA, USA).

Techniques: Immunostaining

Journal: The Journal of International Medical Research

Article Title: Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin

doi: 10.1177/03000605211022297

Figure Lengend Snippet: Univariate analysis of overall survival of patients ( n = 141) with pseudomyxoma peritonei.

Article Snippet: Immunohistochemical staining was performed using primary mouse monoclonal antibodies against Ki67 (clone UMAB107 ready to use; OriGene China, Beijing, China), p53 (clone DO7 ready to use; OriGene China) and CEA (clone COL1 ready to use; OriGene China) that were processed in automated staining equipment (INTELLIPATH FLX®; Biocare Medical, Pacheco, CA, USA).

Techniques:

Journal: The Journal of International Medical Research

Article Title: Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin

doi: 10.1177/03000605211022297

Figure Lengend Snippet: The difference in clinicopathological characteristics between patients ( n = 141) with pseudomyxoma peritonei stratified according to Ki67 and p53 immunostaining levels.

Article Snippet: Immunohistochemical staining was performed using primary mouse monoclonal antibodies against Ki67 (clone UMAB107 ready to use; OriGene China, Beijing, China), p53 (clone DO7 ready to use; OriGene China) and CEA (clone COL1 ready to use; OriGene China) that were processed in automated staining equipment (INTELLIPATH FLX®; Biocare Medical, Pacheco, CA, USA).

Techniques: Immunostaining

Journal: The Journal of International Medical Research

Article Title: Prognostic significance of CEA, Ki67 and p53 in pseudomyxoma peritonei of appendiceal origin

doi: 10.1177/03000605211022297

Figure Lengend Snippet: Multivariate analysis of the association between Ki67/p53 status and the overall survival of patients ( n = 141) with pseudomyxoma peritonei.

Article Snippet: Immunohistochemical staining was performed using primary mouse monoclonal antibodies against Ki67 (clone UMAB107 ready to use; OriGene China, Beijing, China), p53 (clone DO7 ready to use; OriGene China) and CEA (clone COL1 ready to use; OriGene China) that were processed in automated staining equipment (INTELLIPATH FLX®; Biocare Medical, Pacheco, CA, USA).

Techniques:

Journal: Frontiers in Medicine

Article Title: Multi-Site Tumour Sampling Improves the Detection of Intra-Tumour Heterogeneity in Oral and Oropharyngeal Squamous Cell Carcinoma

doi: 10.3389/fmed.2021.670305

Figure Lengend Snippet: Immunohistology. (A) The differential expression of P53 among different small sampling blocks in the same multi-site sampling block. (B) The differential expression of Ki67 among different small sampling blocks in the same multi-site sampling block. (C) The differential expression of CyclinD1 among different small sampling blocks in the same multi-site sampling block. (D) The positive detection rate of two methods. (E) The average positive rate of two methods.

Article Snippet: Tissue sections were incubated with a ready-to-use primary mouse monoclonal anti-p53 (mutant) antibody (clone DO-7, ZSGB-BIO), mouse monoclonal anti-Ki67 antibody (clone GM-001, Gene Tech), and rabbit monoclonal anti-cyclin D1 antibody (clone EP12, ZSGB-BIO), according to the manufacturers' instructions.

Techniques: Quantitative Proteomics, Sampling, Blocking Assay

Journal: Journal of Clinical and Experimental Dentistry

Article Title: Aberrant immunoexpression of p53 tumour-suppressor and Bcl-2 family proteins (Bcl-2 and Bax) in ameloblastomas and odontogenic keratocysts

doi: 10.4317/jced.59769

Figure Lengend Snippet: Immunohistochemical protein expression of p53 (400x). (A) conventonal ameloblastoma; (B) luminal unicystic UA; (C) intraluminal UA; (D) mural UA; (E), OKC non-syndromic or sporadic; (F), OKC related NBSCC; (G), EPC: oral squamous cell carcinoma; (H), ENC: oral squamous cell carcinoma. Abbreviations: UA: unicystic ameloblastoma; EPC: external positive control; ENC: external negative control; OKC: odontogenic keratocyst; NBSCC: naevoid basal cell carcinoma syndrome.

Article Snippet: Primary monoclonal antibodies ( ) from Bio SB Inc. were incubated overnight at 4 °C for mouse anti-human P53 (BSB5842, clone: DO7, Ready-To-Use); mouse anti-human Bcl-2 (BSB5075, clone: BCL2/A4, Concentrated), and rabbit anti-human Bax (BSB6079, clone: E63, Ready-To-Use).

Techniques: Immunohistochemical staining, Expressing, Positive Control, Negative Control

Journal: Cancer Epidemiology Biomarkers & Prevention

Article Title: Effect of Vitamin D on Relapse-Free Survival in a Subgroup of Patients with p53 Protein–Positive Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Trial

doi: 10.1158/1055-9965.epi-19-0986

Figure Lengend Snippet: Figure 2. Typical p53 protein expression patterns on IHC (400). A, Overexpressed p53: Nearly 100% of cellular nuclei in the cancerous region are showing strong p53 positivity (dark brown). Red arrows are pointing to typical strong nuclear accumulation of p53 protein. Slides counterstained in light purple by hematoxylin are negative for p53 protein. In this slide, normal cells in the interstitial area are negative for p53 protein. B, Strongly expressed p53: Part (>10%) of the cellular nuclei in the cancerous region is showing strong p53 positivity (dark brown). Red arrows are pointing to typical strong nuclear accumulation of p53 protein. C, Faintly expressed p53: Part of the cellular nuclei in the cancerous region is showing faint p53 positivity (light brown), and a few cells (10%) are showing strong p53 nuclear accumulation (dark brown). The red arrow is pointing to typical strong nuclear accumulation of p53 protein, but it is rare. Typical faint p53 staining is shown by the hollow red arrows. D, Not expressed p53: Neither strong nor faint p53 cells are found in the cancerous region.

Article Snippet: IHC with primary antibodies against p53 (DO-7) and Ki-67 (SP-6; both from Nichirei Biosciences Inc.) was performed according to the manufacturer's protocols.

Techniques: Expressing, Staining

Journal: Cancer Epidemiology Biomarkers & Prevention

Article Title: Effect of Vitamin D on Relapse-Free Survival in a Subgroup of Patients with p53 Protein–Positive Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Trial

doi: 10.1158/1055-9965.epi-19-0986

Figure Lengend Snippet: Figure 3. Nelson–Aalen cumulative hazard curves in the p53-positive and p53-negative groups. A, In the subgroup of patients with p53-positive cancers, hazard curves for relapse or death of patients taking vitamin D (black line) versus those taking placebo (gray line) are compared. B, In the subgroup of patients with p53-negative cancers, hazard curves for relapse or death of patients taking vitamin D (black line) versus those taking placebo (gray line) are compared. C, In the subgroup of patients with p53-positive cancers, hazard curves for death of patients taking vitamin D (black line) versus those taking placebo (gray line) are compared. D, In the subgroup of patients with p53-negative cancers, hazard curves for death of patients taking vitamin D (black line) versus those taking placebo (gray line) are compared.

Article Snippet: IHC with primary antibodies against p53 (DO-7) and Ki-67 (SP-6; both from Nichirei Biosciences Inc.) was performed according to the manufacturer's protocols.

Techniques:

Journal: Cancer Epidemiology Biomarkers & Prevention

Article Title: Effect of Vitamin D on Relapse-Free Survival in a Subgroup of Patients with p53 Protein–Positive Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Trial

doi: 10.1158/1055-9965.epi-19-0986

Figure Lengend Snippet: Figure 4. Nelson–Aalen cumulative hazard curves for relapse or death of patients with p53-positive cancers stratified by cancer sites. A, In the subgroup of patients with p53- positive colorectal cancer, hazard curves of patients taking vitamin D (black line) versus those taking placebo (gray line) are compared. B, In the subgroup of patients with p53-positive gastric cancer, hazard curves of patients taking vitamin D (black line) versus those taking placebo (gray line) are compared. C, In the subgroup of patients with p53-positive esophageal cancer, hazard curves of patients taking vitamin D (black line) versus those taking placebo (gray line) are compared.

Article Snippet: IHC with primary antibodies against p53 (DO-7) and Ki-67 (SP-6; both from Nichirei Biosciences Inc.) was performed according to the manufacturer's protocols.

Techniques:

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Peptide immunisation of HLA-DR–transgenic mice permits the identification of a novel HLA-DRβ1*0101– and HLA-DRβ1*0401–restricted epitope from p53

doi: 10.1007/s00262-004-0596-7

Figure Lengend Snippet: Scores for HLA-DR1 and HLA-DR4 binding as predicted by SYFPEITHI algorithm and sequences of the peptides used in this study. Predicted peptide core sequence is in bold

Article Snippet: Membranes were then probed overnight at 4°C with antihuman p53 (DO-7) antibody purchased from Pharmingen diluted 1:1,000 in 5% milk TBS-T.

Techniques: Binding Assay, Sequencing

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Peptide immunisation of HLA-DR–transgenic mice permits the identification of a novel HLA-DRβ1*0101– and HLA-DRβ1*0401–restricted epitope from p53

doi: 10.1007/s00262-004-0596-7

Figure Lengend Snippet: Frequency of responses to HA(307) and p53 peptides in HLA-DR–transgenic mice

Article Snippet: Membranes were then probed overnight at 4°C with antihuman p53 (DO-7) antibody purchased from Pharmingen diluted 1:1,000 in 5% milk TBS-T.

Techniques:

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Peptide immunisation of HLA-DR–transgenic mice permits the identification of a novel HLA-DRβ1*0101– and HLA-DRβ1*0401–restricted epitope from p53

doi: 10.1007/s00262-004-0596-7

Figure Lengend Snippet: Responses to p53 candidate peptides in C57BL/6-DR4 mice. a and c C57BL/6-DR4 mice were immunised with p53(29) or p53(63) peptide, and CD8-depleted splenocytes displayed no proliferative responses to the peptide whether tested after one or two in vitro peptide restimulations. b and d No cytokine production was observed in the splenocytes of mice immunised with p53(29) or p53(63) peptide. e CD8-depleted splenocytes of C57BL/6-DR4 mice immunised with p53(108) peptide, displayed peptide-specific proliferation; the HLA-DR restriction of the response was demonstrated by blockade with L243 antibody (data not shown). f IL-5 was produced by splenocytes of immunised mice in response to the p53(108) peptide, but not to the irrelevant peptide HA(307); no IFN-γ production to p53(108) peptide was observed in C57BL/6-DR4 mice (data not shown). Data presented are representative of two independent experiments for p53(29) peptide, three for p53(63) peptide and four for p53(108) peptide. ***p<0.001, unpaired Student’s t test.

Article Snippet: Membranes were then probed overnight at 4°C with antihuman p53 (DO-7) antibody purchased from Pharmingen diluted 1:1,000 in 5% milk TBS-T.

Techniques: In Vitro, Produced

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Peptide immunisation of HLA-DR–transgenic mice permits the identification of a novel HLA-DRβ1*0101– and HLA-DRβ1*0401–restricted epitope from p53

doi: 10.1007/s00262-004-0596-7

Figure Lengend Snippet: Responses of p53(108) peptide–immunised FVB/N-DR1 mice to p53+ tumour cell lysate. SaOs-2/273 have been transfected with p53 bearing the point mutation R→H in position 273, whereas SaOs-2/v have been transfected with the empty vector. a Western blot analysis of the lysate demonstrated that SaOs-2/273 expressed p53 protein, whereas SaOs-2/v showed no detectable level of p53 protein. Following two in vitro restimulations with p53(108) peptide, proliferative responses (b) and IL-5 production (c) were assessed on CD8-depleted splenocytes from peptide-immunised mice. As expected, peptide-specific proliferation and IL-5 production were increased when splenocytes were cocultured with BM-DCs pulsed with the relevant peptide p53(108). Proliferation of DCs was below 300 cpm, and no IL-5 secretion was detected in cultures of DCs alone (data not shown). Proliferation and IL-5 production were also increased in the cocultures of CD8-depleted splenocytes with DCs fed with the p53+ tumour cell lysate from SaOs-2/273, when compared with cocultures with DCs fed with the p53− tumour cell lysate from SaOs-2/v. Data presented are representative of two independent experiments. **p<0.01, unpaired Student’s t test.

Article Snippet: Membranes were then probed overnight at 4°C with antihuman p53 (DO-7) antibody purchased from Pharmingen diluted 1:1,000 in 5% milk TBS-T.

Techniques: Transfection, Mutagenesis, Plasmid Preparation, Western Blot, In Vitro

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Peptide immunisation of HLA-DR–transgenic mice permits the identification of a novel HLA-DRβ1*0101– and HLA-DRβ1*0401–restricted epitope from p53

doi: 10.1007/s00262-004-0596-7

Figure Lengend Snippet: Splenocyte proliferation to p53(108) peptide following p53 cDNA immunisation. FVB/N-DR1 mice were immunised with p53 (273 mutation R→H) cDNA, and splenocyte proliferation was assessed in a 4-day proliferation assay to the peptide. Proliferation of splenocytes cultured with p53(108) peptide was increased as compared to splenocytes cultured with HA(307) peptide or no peptide. Addition of the anti-HLA-DR antibody L243 but not of an isotype-matched antibody blocked the response to p53(108) peptide. **p<0.01, unpaired Student’s t test.

Article Snippet: Membranes were then probed overnight at 4°C with antihuman p53 (DO-7) antibody purchased from Pharmingen diluted 1:1,000 in 5% milk TBS-T.

Techniques: Mutagenesis, Proliferation Assay, Cell Culture

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Peptide immunisation of HLA-DR–transgenic mice permits the identification of a novel HLA-DRβ1*0101– and HLA-DRβ1*0401–restricted epitope from p53

doi: 10.1007/s00262-004-0596-7

Figure Lengend Snippet: Responses to p53(108) peptide in HLA-DR1 and HLA-DR4 healthy donors. T cells from consenting HLA-DR1 and HLA-DR4 healthy donors were sensitised in vitro to p53(108) peptide. After four in vitro restimulations, peptide-specificity was assessed using irradiated allogeneic HLA-DR1+ B-LCL for HLA-DR1 donors or irradiated autologous PBMCs for HLA-DR4 donors as APCs. Peptide-specific proliferations were observed both in HLA-DR1 (a) and in HLA-DR4 (c) donors. Responses were demonstrated to be HLA-DR restricted by blocking with L243 antibody but not with its isotype-matched antibody. b In one case in an HLA-DR1 donor, where the cell numbers permitted, peptide-specific proliferation was correlated with the production of IFN-γ in a peptide-specific manner. Proliferation data presented are representative of the two experiments out of six HLA-DR1 donors and the two experiments out of five HLA-DR4 donors where peptide-specific responses were observed. **p<0.01, unpaired Student’s t test.

Article Snippet: Membranes were then probed overnight at 4°C with antihuman p53 (DO-7) antibody purchased from Pharmingen diluted 1:1,000 in 5% milk TBS-T.

Techniques: In Vitro, Irradiation, Blocking Assay

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Peptide immunisation of HLA-DR–transgenic mice permits the identification of a novel HLA-DRβ1*0101– and HLA-DRβ1*0401–restricted epitope from p53

doi: 10.1007/s00262-004-0596-7

Figure Lengend Snippet: Responses to HA(307) peptide following immunisation of FVB/N-DR1 and C57BL/6-DR4 mice. HLA-DR transgenic were immunised with HA(307) peptide twice at a 1-week interval, and splenocytes were collected and restimulated in vitro with peptide for 6 days. On day 4–5, culture supernatants were collected and reserved for analysis of cytokine production by ELISA. On day 6, these cells were depleted in CD8+ T cells and used as responders in proliferation assays. BM-DCs pulsed with peptide (relevant: HA[307], and irrelevant: p53[108]) were used as APCs. Anti-HLA-DR antibody L243 and an isotype-matched antibody were also added to the cultures in order to assess the HLA-DR restriction of the responses. Cultures were incubated for 60 h and tritiated-thymidine was added 18 h prior to harvesting the cells. Results are presented as means of the cpm of quadruplicate wells. a CD8-depleted splenocytes from FVB/N-DR1 mice proliferated to the HA(307) peptide used for immunisation but not to the irrelevant peptide p53(108). Responses were HLA-DR restricted as demonstrated by blockade of the proliferation by the addition in the cultures of L243 antibody but not of an isotype-matched antibody (HA[307] + L243 vs HA[307] + isotype). b Proliferation data correlated with peptide-specific IFN-γ production in the splenocyte cultures of FVB/N-DR1 mice. c CD8-depleted splenocytes from C57BL/6-DR4–transgenic mice proliferated specifically to the peptide in an HLA-DR–restricted manner. d Proliferation data in C57BL/6-DR4 mice correlated with peptide-specific IFN-γ production. Results presented are representative of 5 independent experiments for FVB/N-DR1 and 4 for C57BL/6-DR4. **p<0.01, unpaired Student’s t test.

Article Snippet: Membranes were then probed overnight at 4°C with antihuman p53 (DO-7) antibody purchased from Pharmingen diluted 1:1,000 in 5% milk TBS-T.

Techniques: Transgenic Assay, In Vitro, Enzyme-linked Immunosorbent Assay, Incubation

Journal: European journal of medicinal chemistry

Article Title: Characterization of a dual degrader of MDM2 and GSPT1.

doi: 10.1016/j.ejmech.2025.117793

Figure Lengend Snippet: Fig. 2. Profiling degraders in OCI-AML3. (A) 72-h anti-proliferation dose response curve of WB156, MD-224, and CC-90009; (B) Western blot of MDM2, p53, and GSPT1 levels following treatment of cells with DMSO or indicated compounds at indicated concentrations for 20 h; quantification of MDM2 (C) p53 (D) and GSPT1 (E) Protein levels based on Western blots. Statistical significance was assessed using unpaired two-tailed t-tests; *p ≤0.05; **p ≤0.01, ***p ≤0.001, ****p ≤0.0001.

Article Snippet: Protein was transferred to polyvinylidene fluoride (PVDF) membranes, then blocked with 5 % non-fat milk, and probed by following primary antibodies: MDM2 (D1V2Z, #86934, 1:1000, CST), p53 (DO-7, #48818, 1:1000, CST), GSPT1/eRF3 (#14980, 1:1000, CST), β-Actin (C4, #sc-47778, 1:1000, Santa Cruz), and Vinculin (#4650, 1:1000, CST).

Techniques: Western Blot, Two Tailed Test

Journal: European journal of medicinal chemistry

Article Title: Characterization of a dual degrader of MDM2 and GSPT1.

doi: 10.1016/j.ejmech.2025.117793

Figure Lengend Snippet: Fig. 3. Profiling degraders in Kasumi-1. (A) 72-h anti-proliferation dose response curve of WB156, MD-224, and CC-90009; (B) Western blot of MDM2, p53, and GSPT1 levels following treatment of cells with DMSO or indicated compounds at indicated concentrations for 20 h; quantification of MDM2 (C) and GSPT1 (D) protein levels based on Western blots. Statistical significance was assessed using unpaired two-tailed t-tests; *p ≤0.05; **p ≤0.01, ***p ≤0.001, ****p ≤0.0001.

Article Snippet: Protein was transferred to polyvinylidene fluoride (PVDF) membranes, then blocked with 5 % non-fat milk, and probed by following primary antibodies: MDM2 (D1V2Z, #86934, 1:1000, CST), p53 (DO-7, #48818, 1:1000, CST), GSPT1/eRF3 (#14980, 1:1000, CST), β-Actin (C4, #sc-47778, 1:1000, Santa Cruz), and Vinculin (#4650, 1:1000, CST).

Techniques: Western Blot, Two Tailed Test

Journal: European journal of medicinal chemistry

Article Title: Characterization of a dual degrader of MDM2 and GSPT1.

doi: 10.1016/j.ejmech.2025.117793

Figure Lengend Snippet: Fig. 4. Profiling degraders in CCRF-CEM. (A) 72-h anti-proliferation dose response curve of WB156, MD-224, and CC-90009; (B) Western blot of MDM2, p53, and GSPT1 levels following treatment of cells with DMSO or indicated compounds at indicated concentrations for 20 h; quantification of MDM2 (C) and GSPT1 (D) protein levels based on Western blots. Statistical significance was assessed using unpaired two-tailed t-tests; *p ≤0.05; **p ≤0.01, ***p ≤0.001, ****p ≤0.0001.

Article Snippet: Protein was transferred to polyvinylidene fluoride (PVDF) membranes, then blocked with 5 % non-fat milk, and probed by following primary antibodies: MDM2 (D1V2Z, #86934, 1:1000, CST), p53 (DO-7, #48818, 1:1000, CST), GSPT1/eRF3 (#14980, 1:1000, CST), β-Actin (C4, #sc-47778, 1:1000, Santa Cruz), and Vinculin (#4650, 1:1000, CST).

Techniques: Western Blot, Two Tailed Test